The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-β (Aβ) Aggregation: Potential Therapeutics of Alzheimer’s Disease
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease with no clinically accepted treatment to cure or halt its progression. The worldwide effort to develop peptide-based inhibitors of amyloid-β (Aβ) aggregation can be considered an unplanned combinatorial experiment. An understanding of what has been done and achieved may advance our understanding of AD pathology and the discovery of effective therapeutic agents. We review here the history of such peptide-based inhibitors, including those based on the Aβ sequence and those not derived from that sequence, containing both natural and unnatural amino acid building blocks. Peptide-based aggregation inhibitors hold significant promise for future AD therapy owing to their high selectivity, effectiveness, low toxicity, good tolerance, low accumulation in tissues, high chemical and biological diversity, possibility of rational design, and highly developed methods for analyzing their mode of action, proteolytic stability (modified peptides), and blood-brain barrier (BBB) permeability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Principles of protein-protein interactions
Jones, S., & Thornton, J. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.13 · Cited by 2,684
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
The Protein-Folding Problem, 50 Years On
Dill, K. A., & MacCallum, J. L. (2012) · Science · doi:10.1126/science.1219021 · Cited by 1,699
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663
Research works printed but not linked: 248
- Alzheimer A., 1907, Allg. Zschr. Psychiat. Psych. gerichtl. Med., 64, 146
- Hippius H., 2003, Dialogues Clin. Neurosci., 5, 101, 10.31887/DCNS.2003.5.1/hhippius · DOI · Paper page
- 10.1007/978-94-007-5416-4_14 · DOI · Paper page
- 10.1016/j.jalz.2016.07.150 · DOI · Paper page
- 10.1016/j.jalz.2010.01.010 · DOI · Paper page
- 10.1016/j.jalz.2007.04.381 · DOI · Paper page
- 10.1146/annurev.publhealth.23.100901.140525 · DOI · Paper page
- 10.1126/science.275.5300.630 · DOI · Paper page
- Selkoe D. J., 2001, Physiol. Rev., 81, 741, 10.1152/physrev.2001.81.2.741 · DOI · Paper page
- 10.1002/syn.20957 · DOI
- 10.1001/jamaneurol.2016.0301 · DOI
- 10.1016/0896-6273(89)90210-9 · DOI · Paper page
- 10.2353/ajpath.2007.070345 · DOI · Paper page
- 10.1111/j.1471-4159.2007.04809.x · DOI
- 10.1021/cr3000994 · DOI · Paper page
- 10.1016/S0076-6879(99)09015-1 · DOI · Paper page
- 10.1159/000100355 · DOI · Paper page
- 10.1021/bi0011330 · DOI · Paper page
- 10.1002/jnr.10859 · DOI · Paper page
- 10.1021/bi00172a009 · DOI
- 10.1016/j.cell.2012.02.022 · DOI · Paper page
- 10.1038/nn.3028 · DOI · Paper page
- 10.1186/1750-1326-4-48 · DOI · Paper page
- 10.1126/science.1213151 · DOI · Paper page
- 10.1021/acs.jpclett.5b00055 · DOI
- 10.1080/07391102.2016.1199972 · DOI
- 10.1039/C6RA10934A · DOI
- 10.1073/pnas.1411798111 · DOI · Paper page
- 10.1016/j.biochi.2014.12.007 · DOI · Paper page
- 10.1002/slct.201600078 · DOI
- 10.1039/C5RA19015K · DOI
- 10.1021/jp200743w · DOI
- 10.1021/jp1062572 · DOI
- 10.1021/acs.jpcb.5b09678 · DOI
- 10.1016/j.bpc.2016.03.001 · DOI
- 10.1016/j.bpc.2010.05.001 · doi:10.1016/j.bpc.2010.05.001
- 10.1098/rsif.2015.0876 · DOI
- 10.1080/07391102.2012.703062 · DOI
- 10.1021/acs.jpcb.6b09216 · DOI
- 10.1002/psc.2789 · DOI · Paper page
- 10.1590/S1807-59322011001300006 · DOI · Paper page
- 10.1021/ja054041c · DOI · Paper page
- 10.1016/j.bbrc.2005.10.006 · DOI
- 10.1111/j.1471-4159.2005.03576.x · DOI
- 10.1038/85525 · DOI · Paper page
- 10.1016/j.jmb.2011.12.062 · DOI · Paper page
- 10.1038/nature03659 · DOI · Paper page
- 10.1073/pnas.0408007101 · DOI
- 10.1038/nrd2896 · DOI · Paper page
- 10.1038/nrd2676 · DOI
- 10.3389/fnagi.2014.00165 · DOI
- 10.1016/B978-0-12-394816-8.00004-0 · DOI
- 10.2174/157488911795933938 · DOI
- Vincent B., 2011, J. Alzheimers Dis., 24, 75, 10.3233/JAD-2011-110218 · DOI
- 10.1001/archneurol.2012.2194 · DOI · Paper page
- 10.1016/j.jalz.2013.05.569 · DOI
- 10.1038/nn.2433 · DOI · Paper page
- 10.1039/C4RA09193K · DOI
- 10.1021/cr300009x · DOI · Paper page
- 10.1016/S1474-4422(08)70167-4 · DOI · Paper page
- 10.1159/000358875 · DOI
- 10.1111/j.1476-5381.2011.01713.x · DOI
- 10.2174/156720511796717122 · DOI
- 10.1073/pnas.1208797109 · DOI
- 10.1212/WNL.0000000000001877 · DOI · Paper page
- 10.2174/13816128113199990068 · DOI
- 10.2174/156802607779318262 · DOI · Paper page
- 10.2174/092986712802430018 · doi:10.2174/092986712802430018
- 10.1016/j.expneurol.2009.08.032 · DOI
- 10.1002/cmdc.201500215 · DOI
- 10.1038/nbt1273 · DOI · Paper page
- 10.1016/j.jmgm.2005.08.002 · DOI
- 10.1038/nature06526 · DOI · Paper page
- 10.1007/s11030-006-9035-3 · DOI
- 10.1126/science.1101262 · DOI · Paper page
- 10.1073/pnas.0705888104 · DOI
- 10.1038/nm790 · DOI · Paper page
- 10.1126/science.1151839 · DOI · Paper page
- 10.1073/pnas.1600749113 · DOI · Paper page
- 10.1073/pnas.262663499 · DOI · Paper page
- 10.1110/ps.041292205 · DOI · Paper page
- 10.1371/journal.pone.0090385 · DOI
- 10.1016/j.sbi.2014.12.004 · DOI · Paper page
- 10.1038/aps.2011.14 · DOI · Paper page
- 10.1517/13543776.2013.772983 · DOI
- 10.2174/092986711797200435 · DOI
- 10.1021/co5001234 · doi:10.1021/co5001234
- 10.1016/j.neurobiolaging.2006.02.015 · DOI · Paper page
- 10.1006/jmbi.1998.1677 · DOI
- 10.2174/138955751513150923101841 · doi:10.2174/138955751513150923101841
- 10.1074/jbc.M508246200 · DOI · Paper page
- 10.1155/2014/350516 · DOI
- 10.1021/jo4020722 · DOI
- 10.1021/ar020147q · doi:10.1021/ar020147q
- 10.1021/ol902131n · DOI
- 10.1039/c3ra44318c · doi:10.1039/c3ra44318c
- 10.1002/ejoc.201101744 · doi:10.1002/ejoc.201101744
- 10.1039/C5CS00889A · DOI · Paper page
- 10.1038/nchem.2476 · DOI · Paper page
- 10.2174/0929867323666160909155222 · DOI
- 10.1016/j.drudis.2014.10.003 · DOI · Paper page
- 10.2174/138161212799277752 · DOI
- 10.4161/pri.28220 · DOI
- 10.1016/j.bmc.2015.02.041 · DOI
- 10.2174/138955712800493942 · DOI
- 10.1074/jbc.M211976200 · DOI · Paper page
- 10.2174/1874070701105010039 · DOI
- 10.1021/ar8000475 · DOI · Paper page
- Doig A. J., 2007, Curr. Opin. Drug Discovery Devel., 10, 533
- 10.1002/ddr.10074 · DOI
- 10.1021/acschemneuro.6b00154 · DOI
- 10.1074/jbc.272.19.12601 · DOI · Paper page
- 10.1016/j.regpep.2004.03.013 · DOI
- 10.1006/bbrc.1996.1413 · DOI · Paper page
- 10.1038/nm0798-822 · DOI · Paper page
- 10.1096/fj.01-0841fje · DOI · Paper page
- 10.1038/sj.mp.4001516 · DOI
- 10.1007/0-387-23226-5_18 · DOI
- 10.1016/j.nbd.2004.08.007 · DOI
- Granic I., 2010, J. Alzheimers Dis., 19, 991, 10.3233/JAD-2010-1297 · DOI
- 10.1074/jbc.M113.537472 · DOI
- 10.1021/bi002734u · DOI · Paper page
- 10.1021/bi982119e · DOI · Paper page
- 10.1016/S1074-5521(03)00022-X · DOI
- 10.1021/bi701415b · DOI · Paper page
- 10.1021/bm401795e · DOI
- 10.1021/bi982824n · DOI · Paper page
- 10.3109/13506120108993819 · DOI
- 10.1002/(SICI)1097-4695(19990605)39:3<371::AID-NEU4>3.3.CO;2-5 · doi:10.1002/(sici)1097-4695(19990605)39:3<371::aid-neu4>3.3.co;2-5
- 10.1046/j.1471-4159.1996.66041599.x · DOI
- 10.1021/bi002416v · DOI · Paper page
- 10.1034/j.1399-3011.2002.11002.x · DOI · Paper page
- 10.1111/j.1399-3011.2004.00156.x · DOI
- 10.1002/cmdc.200900191 · DOI
- 10.2174/1568026024607508 · DOI
- 10.1074/jbc.M212694200 · DOI
- 10.1007/s00044-012-0386-2 · DOI
- 10.1021/bc025526i · DOI
- 10.1006/bbrc.2001.6191 · DOI
- 10.1034/j.1399-3011.2003.21028.x · DOI
- 10.1021/bi0259857 · DOI
- 10.1021/bi050225s · DOI
- 10.1074/jbc.M305466200 · DOI
- 10.1021/bi060837s · DOI · Paper page
- 10.1021/bi300415v · DOI
- http://adisinsight.springer.com/drugs/800027384.
- 10.1021/ja0600678 · DOI
- 10.1002/cbic.200700338 · DOI
- 10.1002/bip.21151 · DOI
- 10.1021/bc900281b · DOI
- 10.1016/j.ejmech.2008.03.036 · DOI
- 10.1111/j.1747-0285.2011.01259.x · DOI
- 10.1016/j.bbrc.2009.01.090 · DOI
- 10.1021/cn900019r · DOI
- 10.1002/psc.1109 · DOI
- 10.1002/cbic.201600243 · DOI
- 10.1006/jmbi.2000.3711 · DOI · Paper page
- 10.1039/c3mb70235a · DOI
- 10.1016/j.peptides.2010.06.033 · DOI
- 10.1021/bi100144m · DOI · Paper page
- 10.1371/journal.pone.0054769 · DOI
- 10.1016/j.nano.2016.10.006 · DOI
- 10.1016/j.bmc.2010.06.087 · DOI
- 10.1016/j.bmcl.2011.07.111 · DOI
- 10.1016/j.ab.2012.11.025 · DOI
- 10.1039/C3TB21483D · DOI
- 10.1002/anie.201405109 · DOI
- 10.1002/cbic.201402430 · DOI
- 10.1016/j.bmcl.2015.05.027 · DOI
- 10.1002/psc.2784 · DOI
- 10.1038/srep08139 · DOI
- 10.1021/acschemneuro.6b00175 · DOI
- 10.1021/acsami.5b00915 · DOI · Paper page
- 10.1002/chem.201404562 · DOI · Paper page
- 10.1002/smll.201202612 · DOI
- 10.1046/j.1471-4159.1995.64010253.x · DOI · Paper page
- Pike C. J., 1993, J. Neurosci., 13, 1676, 10.1523/JNEUROSCI.13-04-01676.1993 · DOI · Paper page
- 10.1006/bbrc.2002.6745 · DOI
- 10.1073/pnas.0807163105 · DOI · Paper page
- 10.1021/bi902075h · DOI
- 10.1021/jm200982p · DOI
- 10.1016/j.npep.2010.03.001 · DOI
- 10.1016/j.bbrc.2011.02.067 · DOI
- 10.1021/acschemneuro.6b00006 · DOI
- 10.1097/00001756-199906030-00013 · doi:10.1097/00001756-199906030-00013
- 10.1016/j.bbrc.2004.09.024 · DOI
- 10.1074/jbc.M003554200 · DOI · Paper page
- 10.1042/bst0300537 · doi:10.1042/bst0300537
- 10.1039/B312129A · DOI · Paper page
- 10.1016/j.bmc.2011.01.021 · DOI
- 10.1016/j.bmc.2013.08.062 · DOI
- 10.1021/jm901092h · DOI
- 10.1016/j.peptides.2003.08.005 · DOI
- 10.1111/j.1527-3458.2005.tb00053.x · DOI
- 10.1124/jpet.107.130526 · DOI · Paper page
- 10.1023/B:MCBI.0000049373.15558.b8 · DOI
- 10.1080/13506120500350762 · DOI
- 10.1371/journal.pone.0027649 · DOI
- 10.1371/journal.pone.0068159 · DOI
- Herculano B., 2013, J. Alzheimers Dis., 33, 983, 10.3233/JAD-2012-121324 · DOI
200 of 248 shown
Cited by
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
“The physicochemical factors that influence BBB permeability include molecular weight, charge, lipid solubility, surface activity and relative size of the molecule [2].”
BackgroundRecent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Dominguez, L., Shea, J.-E., Dokholyan, N. V., De Simone, A., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 678
Multicomponent peptide assemblies
Raymond, D. M., & Nilsson, B. L. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00115d · Cited by 346
Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
Teleanu, R. I., Preda, M. D., Niculescu, A.-G., Vladâcenco, O., Radu, C. I., Grumezescu, A. M., & Teleanu, D. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050987 · Cited by 200
Metadata
- Authors
- Goyal, D., Shuaib, S., Mann, S., & Goyal, B.
- Venue
- ACS Combinatorial Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-01-18
- Volume
- 19
- Issue
- 2
- Pages
- 55-80
- ISSN
- 2156-8944 (ISSN-L)
- 2156-8952
- OpenAlex
- W2564069686
- Cited by
- 227
- References
- 22
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Science and Engineering Research Board (SB/FT/CS-013/2014, SERB/F/4167/2015-16)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-β (Aβ) Aggregation: Potential Therapeutics of Alzheimer’s Disease. https://app.cochat.ai/papers/10.1021/acscombsci.6b00116
- The paper
- Goyal, D., Shuaib, S., Mann, S., & Goyal, B. (2017). Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-β (Aβ) Aggregation: Potential Therapeutics of Alzheimer’s Disease. ACS Combinatorial Science. https://doi.org/10.1021/acscombsci.6b00116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.